The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma

Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomid...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Shigeo, Kuroha, Takashi, Yano, Toshio, Sato, Naoko, Furukawa, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109573/
https://www.ncbi.nlm.nih.gov/pubmed/27746443
_version_ 1782467568708091904
author Hashimoto, Shigeo
Kuroha, Takashi
Yano, Toshio
Sato, Naoko
Furukawa, Tatsuo
author_facet Hashimoto, Shigeo
Kuroha, Takashi
Yano, Toshio
Sato, Naoko
Furukawa, Tatsuo
author_sort Hashimoto, Shigeo
collection PubMed
description Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomide, and dexamethasone, adding bortezomib after starting the three-drug combination therapy. This patient has remained in a stable disease state since the beginning of this therapy. Regarding the other four cases, a partial response and a prolonged survival for approximately one year were noted. Peripheral neuropathy did not increase after thalidomide addition. Adding low-dose thalidomide may safely improve the responses for multiple myeloma refractory to bortezomib and dexamethasone.
format Online
Article
Text
id pubmed-5109573
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-51095732016-11-17 The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma Hashimoto, Shigeo Kuroha, Takashi Yano, Toshio Sato, Naoko Furukawa, Tatsuo Intern Med Case Report Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomide, and dexamethasone, adding bortezomib after starting the three-drug combination therapy. This patient has remained in a stable disease state since the beginning of this therapy. Regarding the other four cases, a partial response and a prolonged survival for approximately one year were noted. Peripheral neuropathy did not increase after thalidomide addition. Adding low-dose thalidomide may safely improve the responses for multiple myeloma refractory to bortezomib and dexamethasone. The Japanese Society of Internal Medicine 2016-10-15 /pmc/articles/PMC5109573/ /pubmed/27746443 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hashimoto, Shigeo
Kuroha, Takashi
Yano, Toshio
Sato, Naoko
Furukawa, Tatsuo
The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_full The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_fullStr The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_full_unstemmed The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_short The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
title_sort addition of low-dose thalidomide to bortezomib and dexamethasone for refractory multiple myeloma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109573/
https://www.ncbi.nlm.nih.gov/pubmed/27746443
work_keys_str_mv AT hashimotoshigeo theadditionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT kurohatakashi theadditionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT yanotoshio theadditionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT satonaoko theadditionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT furukawatatsuo theadditionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT hashimotoshigeo additionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT kurohatakashi additionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT yanotoshio additionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT satonaoko additionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma
AT furukawatatsuo additionoflowdosethalidomidetobortezomibanddexamethasoneforrefractorymultiplemyeloma

Ejemplares similares